ANN 102
Alternative Names: ANN-102; APJ-RA - Anodyne NanotechLatest Information Update: 23 Jun 2025
At a glance
- Originator Anodyne Nanotech
- Class
- Mechanism of Action Apelin receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Sarcopenia
Most Recent Events
- 23 Jun 2025 Anodyne Nanotech has patents pending for microneedles and microneedle patches for transdermal drug delivery and methods of making and using the same in USA, Israel, Europe, South Korea, Japan, Australia, Mexico, Brazil, Canada and worldwide
- 23 Jun 2025 Pharmacodynamics data from a preclinical trial in Sarcopenia released by Anodyne Nanotech (Anodyne Nanotech pipeline, June 2025)
- 09 Jun 2025 ANN 102 is available for licensing as of 09 Jun 2025. https://www.theheropatch.com/